The CEO of Context Therapeutics on raising $100M for a Claudin 6 x CD3 bispecific this month

blonca9
May 21, 2024
1 min read

Martin Lehr describes how Nextech enabled this private placement that may allow the company to accelerate clinical development to additional types of cancer in the future.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

The CEO of Context Therapeutics on raising $100M for a Claudin 6 x CD3 bispecific this month

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight